The first drug to be approved with activity against the ERK1/2 pathway was the pan-RAF inhibitor Sorafenib [83] but efforts to inhibit RAF were galvanised by the discovery of BRAFV600E mutations in melanoma [23,84]. This evidence concerns the gene MAPK3 and melanoma.